Steven Joffe of the Perelman School of Medicine said the federal government, drug companies, and insurers would likely be unwilling to pay for custom pharmaceutical drugs. “Unfortunately, that leaves it to families,” he said. “It feels awfully uncomfortable, but that is the reality.”

October 9, 2019 ・ From The New York Times